Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes

Mark R. Nehler,Eric P. Brass,Richard Anthony,John Dormandy,Jenny Jiao,Thomas O. McNamara,William R. Hiatt, Null Null

Journal of Vascular Surgery（2007）

引用 45|浏览8

暂无评分

摘要

Conclusion Eight weeks of parenteral therapy with lipo-ecraprost after distal revascularization in patients with CLI provided no additional benefit in the reduction of major amputation or death at 180 days.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要